165
Views
13
CrossRef citations to date
0
Altmetric
Articles

The Apoptotic, Cytotoxic, and Antiangiogenic Impact of Linum usitatissimum Seed Essential Oil Nanoemulsions on the Human Ovarian Cancer Cell Line A2780

, , &
Pages 2388-2396 | Received 28 Apr 2020, Accepted 10 Sep 2020, Published online: 22 Sep 2020
 

Abstract

Background

Linum usitatissimum seed essential oil (LSEO) has been used to reduce the risk of prostate and colon cancer. In this study, we optimized the bio-accessibility and bio-compatibility of LSEO to evaluate its cytotoxic, apoptotic and anti-angiogenic impact on the human ovarian cancer cell line A2780.

Method

We produced LSEO nanoemulsions (LSEO-NEs) utilizing the ultrasound-based technique and the size, its droplets’ morphology and stability were characterized. LSEO-NE cytotoxicity was studied by estimating the viability of A2780 human ovarian cancer cell and normal human foreskin fibroblasts (HFFS). Their apoptotic activity was evaluated measuring the Caspase-3, 8 and nine gene expression. Finally, its anti-angiogenic potential was measured applying Chick Chorioallantoic Membrane (CAM) assay.

Results

A significant dose-dependent cytotoxic impact of LSEO-NE was detected in the A2780 cells and not in HFF cellsThe apoptotic genes expression profile confirmed the A2780 cell apoptosis death. Moreover, the reduction in length and number of blood vessels in the CAM assay demonstrated the anti-angiogenic activity of LSEO-NE.

Conclusion

The cancer cell-selective cytotoxicity apoptosis, and anti-angiogenic effects of LSEO-NE indicate its potential as a novel anticancer compound. However, further cell lines have to be analyzed in case of its potential anticancer impacts on human ovarian cancer cells.

Disclosure Statement

The authors have declared no conflict of interest.

Funding

This work was supported by Islamic Azad University, Mashhad, Iran. Therefore is appreciated by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.